Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021

被引：3

作者：

Glover, Michael ^{[1
]}

Hui, Gavin ^{[1
]}

Chiang, Ryan ^{[1
]}

Savage, Philip ^{[2
]}

Krell, Jonathan ^{[3
]}

Julve, Maximilian ^{[3
]}

Grivas, Petros ^{[4
]}

Lythgoe, Mark ^{[3
]}

Khaki, Ali Raza ^{[5
]}

机构：

[1] Stanford Univ, Dept Med, Stanford, CA 94305 USA

[2] Brighton & Sussex Univ Hosp NHS Trust, Dept Oncol, Brighton, E Sussex, England

[3] Hammersmith Hosp, Imperial Coll London, Dept Surg & Canc, London, England

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Med Oncol,Clin Res Div, Seattle, WA USA

[5] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

来源：

BJU INTERNATIONAL | 2022年 / 129卷 / 02期

关键词：

D O I：

10.1111/bju.15629

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：168 / 170

页数：3

共 50 条

[41] Drug Induced Anaphylaxis in Korean: Data from the Adverse Drug Reaction Reporting System to the Korea Food and Drug Administration
Jung, J. W.
Kang, H. R.
Lee, Y. R.
DRUG SAFETY, 2013, 36 (09) : 850 - 850
[42] Adverse events reported to the US Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel
Dores, Graca M.
Jason, Christopher
Niu, Manette T.
Perez-Vilar, Silvia
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1087 - 1100
[43] Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
Zhang, Ying
Ran, Li
Liang, Yongchao
Zhang, Yanqiu
An, Zhuoling
FRONTIERS IN PHARMACOLOGY, 2023, 14
[44] Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
Sridhara, Rajeshwari
Johnson, John R.
Justice, Robert
Keegan, Patricia
Chakravarty, Aloka
Pazdur, Richard
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (04): : 230 - 243
[45] Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
Enrique Seoane-Vazquez
Rosa Rodriguez-Monguio
John H. Powers
Scientific Reports, 14
[46] Use of Clinical Outcome Assessments in New Drug Approvals by the US Food and Drug Administration Divisions of Neurology I and II
Schein, Yvette
Fernandez Lynch, Holly
JAMA NETWORK OPEN, 2022, 5 (09)
[47] Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.
Khaki, Ali Raza
Desai, Aakash
Schoen, Martin W.
Gyawali, Bishal
Chen, Eddy J.
Yang, Peter C.
Warner, Jeremy Lyle
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] Direct Oral Anticoagulants and Menorrhagia in Premenopausal Women: Data from the Food and Drug Administration Adverse Event Reporting System and US Drug Utilization
Tobenkin, A.
Mohamoud, M.
Munoz, M.
Waldron, P.
HAEMOPHILIA, 2017, 23 : 43 - 43
[49] Comments on "The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020"
Jakobsen, Anders K. M.
Spindler, Karen-Lise Garm
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) : 1423 - 1424
[50] Amnesia as an Adverse Event Associated With Fentanyl: An Analysis of the US Food and Drug Administration Adverse Event Reporting System, 2011-2021
Barash, Jed A.
Kofke, W. Andrew
Demaria, Alfred, Jr.
JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2024, 36 (01) : 88 - 89

← 1 2 3 4 5 →